Introduction

The United States was the first major regulatory jurisdiction to implement a comprehensive Unique Device Identification (UDI) framework for medical devices. The U.S. Food and Drug Administration (FDA) published the UDI Final Rule on 24 September 2013, establishing standardized requirements for device identification, labelling, and data submission to improve traceability, strengthen post-market surveillance, and enhance patient safety. The rule became effective on 24 September 2014, with implementation phased by device risk classification over several years.

The FDA’s UDI framework aligns with internationally recognized identification standards through FDA-accredited issuing agencies while establishing its own regulatory requirements for UDI assignment, device labelling, direct marking, and device identification. Since its introduction, the FDA’s framework has influenced the development of UDI regulations in many other jurisdictions, including the European Union, Australia, and Switzerland.

This article provides an overview of the FDA’s UDI framework, explaining its purpose, stakeholder responsibilities, key regulatory identifiers, compliance obligations, implementation requirements, and the role of trusted product data in supporting long-term UDI compliance.

The Strategic Purpose of the FDA UDI Framework

The publication of the UDI Final Rule in September 2013 introduced a standardized system for uniquely identifying medical devices marketed in the United States. Through a phased implementation beginning in September 2014, the framework established consistent device identification across manufacturing, distribution, clinical use, and post-market activities while supporting greater transparency throughout the healthcare ecosystem.

The primary objectives of the FDA’s UDI framework are to:

• Improve device identification and traceability: Establish a standardized system for uniquely identifying medical devices throughout distribution and clinical use.
• Strengthen patient safety: Facilitate faster and more accurate recalls, adverse event investigations, and other corrective actions through standardized device identification.
• Enhance post-market surveillance: Improve the FDA’s ability to monitor device performance, identify safety trends, and respond more effectively to emerging public health concerns.
• Reduce medical errors: Enable healthcare providers to more accurately identify medical devices, supporting safer clinical decision-making and more reliable device documentation.
• Promote standardized device identification: Establish a consistent identification framework based on internationally recognized standards, enabling broader adoption of UDI principles across the global healthcare industry.

Scope and Stakeholder Responsibilities

The FDA’s UDI requirements apply to most medical devices distributed in the United States, with implementation introduced through a phased, risk-based approach and subject to specific exemptions and exceptions defined in the UDI Rule.

The framework establishes responsibilities across several stakeholders.

• Labelers: Under the FDA UDI Rule, the labeler is responsible for assigning UDIs, ensuring compliant device labelling, maintaining device identification information, and submitting required device information to the FDA’s Global Unique Device Identification Database (GUDID). In most cases, the labeler is the device manufacturer, although other organizations may assume this role depending on how the device is labelled and commercially distributed.
• Manufacturers: Manufacturers are responsible for maintaining accurate product information, supporting compliant UDI assignment and labelling, and ensuring device changes are appropriately reflected throughout the product lifecycle. Where the manufacturer is not the labeler, close coordination between both organizations is essential to ensure device information remains accurate and current.
• Distributors and Healthcare Providers: Although they do not have primary UDI compliance responsibilities under the FDA UDI Rule, distributors and healthcare providers use UDI information to support device identification, inventory management, recalls, adverse event reporting, and other post-market activities throughout the healthcare system.

Key Regulatory Components of the FDA UDI Framework

The FDA’s UDI framework combines standardized device identification, accredited issuing agencies, and a centralized repository for device identification information. Together, these components establish a consistent approach to identifying medical devices throughout their lifecycle and support the FDA’s broader objectives for traceability, post-market surveillance, and patient safety.

• Unique Device Identification (UDI) – Every applicable medical device must be assigned a UDI using an FDA-accredited issuing agency. The UDI uniquely identifies the device model while also supporting production-level traceability.
• FDA-Accredited Issuing Agencies – The FDA currently recognizes issuing agencies including GS1, HIBCC, and ICCBBA. These organizations establish the coding standards used to generate compliant UDIs.
• Global Unique Device Identification Database (GUDID) – GUDID serves as the FDA’s repository for key device information associated with each Device Identifier (DI), making standardized device identification available to regulators, healthcare providers, distributors, and the public.

Together, these components establish the FDA’s regulatory framework for standardized identification and traceability of medical devices throughout their lifecycle.

Key Regulatory Identifiers

The FDA’s UDI framework relies on standardized identifiers that distinguish a device model from its production-specific characteristics.

• UDI-DI: The Device Identifier (DI) is the static portion of the UDI that uniquely identifies a specific device model. It forms the primary identifier used throughout the FDA’s UDI framework and serves as the key submitted to GUDID.
• UDI-PI: The Production Identifier (PI) contains variable production information such as lot number, serial number, manufacturing date, expiration date, or software version, where applicable. Unlike the DI, the PI supports production-level traceability and appears on the device label rather than being maintained as part of the core GUDID device record.
• Issuing Agencies: UDI identifiers must be generated using an FDA-accredited issuing agency, ensuring standardized device identification across the U.S. healthcare system.

High-Level Obligations for Compliance

Achieving compliance with the FDA’s UDI Rule requires organizations to establish governance processes that maintain accurate device information throughout the product lifecycle.

• UDI Assignment: Assign UDIs to applicable devices using an FDA-accredited issuing agency. The UDI must include a Device Identifier (DI) and, where required, applicable Production Identifier (PI) information.
• UDI Labelling: Apply the UDI to device labels and applicable packaging in both plain-text human-readable format and Automatic Identification and Data Capture (AIDC) format, unless an exception or alternative applies.
• Direct Marking: Permanently mark the UDI on devices intended to be used more than once and reprocessed before each use, where required under FDA regulations.
• GUDID Data Submission: Submit required DI records and associated device attributes to the Global Unique Device Identification Database (GUDID), and maintain those records as device information changes.
• Change Management: Assess product, packaging, labelling, or regulatory changes to determine whether an existing UDI record must be updated or whether a new DI is required.
• Lifecycle Data Governance: Keep UDI information aligned across device labelling, GUDID records, quality systems, regulatory documentation, and internal source systems throughout the product lifecycle.
• Post-Market Use: Use UDI information to support adverse event reporting, recalls, corrections, removals, device tracking, and other post-market activities.

FDA Compared with Other Global UDI Frameworks

Although the FDA’s UDI framework shares many common principles with other global UDI programs, each jurisdiction has its own regulatory framework, competent authority, database, and compliance responsibilities.

Topic	United States	European Union	Australia	Switzerland
Competent Authority	FDA	European Commission & Member State Competent Authorities	Therapeutic Goods Administration (TGA)	Swissmedic
Regulatory Framework	FDA UDI Rule	MDR / IVDR	Australian UDI Framework	MedDO / IvDO
Regulatory Database	GUDID	EUDAMED	AusUDID	swissdamed
Responsible Party for UDI Submission	Labeler	Manufacturer	Sponsor	Manufacturer

Although the three jurisdictions share many common UDI principles, each has its own regulatory framework, submission requirements, and responsible parties. Manufacturers supplying devices globally should establish governance processes that enable consistent management of UDI data while supporting jurisdiction-specific compliance obligations.

Compliance Timeline

The FDA implemented the UDI Rule through a phased, risk-based approach, introducing compliance requirements progressively according to device risk classification. This allowed manufacturers and labelers to transition to standardized device identification while minimizing disruption across the healthcare industry.

Device Category	UDI Compliance Deadline
Class III Devices	24 September 2014 (In Effect)
Implantable, Life-Supporting and Life-Sustaining Devices	24 September 2015 (In Effect)
Class II Devices	24 September 2016 (In Effect)
Class I Devices and Unclassified Devices	24 September 2018 (In Effect)

Although the phased implementation has been completed, manufacturers and labelers remain responsible for maintaining ongoing UDI compliance. This includes submitting and maintaining device records in GUDID, assigning UDIs to applicable devices, maintaining compliant device labelling, applying direct marking where required, and ensuring UDI information remains accurate throughout the product lifecycle.

Strategic Value Beyond Compliance

The FDA’s UDI framework provides a standardized foundation for identifying medical devices throughout their lifecycle. Beyond regulatory compliance, effective UDI management improves traceability, strengthens post-market surveillance, and supports more consistent device information across regulatory, quality and supply chain systems.

Manufacturers that establish governed product data and repeatable UDI submission processes are better positioned to maintain compliance, manage product changes efficiently, and reuse trusted product information across multiple global UDI frameworks.